assessed the clinicopathological correlation and prognostic significance of ARID1A expression by an immunohistochemical study: they proved that low level of ARID1A was significantly correlated with higher nuclear grade, advanced pTNM stage, and shorter cancer-specific and progression-free survival. This evidence concerns the gene ARID1A and cancer.